Chia-Ying Liu1, Jianhua Yao1, William C Kovacs1, Joseph A Shrader1, Galen Joe1, Ronald Ouwerkerk1, Ami K Mankodi1, William A Gahl1, Ronald M Summers1, Nuria Carrillo2. 1. From Radiology and Imaging Sciences (C.-Y.L., J.Y., W.C.K., R.M.S.) and Rehabilitation Medicine Department (J.A.S., G.J.), Clinical Center, National Institute of Diabetes and Digestive and Kidney Diseases (R.O.), Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (A.K.M.), and Medical Genetics Branch, National Human Genome Research Institute (W.A.G., N.C.), NIH, Bethesda, MD. 2. From Radiology and Imaging Sciences (C.-Y.L., J.Y., W.C.K., R.M.S.) and Rehabilitation Medicine Department (J.A.S., G.J.), Clinical Center, National Institute of Diabetes and Digestive and Kidney Diseases (R.O.), Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (A.K.M.), and Medical Genetics Branch, National Human Genome Research Institute (W.A.G., N.C.), NIH, Bethesda, MD. nuri.carrillo@gmail.com.
Abstract
OBJECTIVE: To characterize muscle involvement and evaluate disease severity in patients with GNE myopathy using skeletal muscle MRI and proton magnetic resonance spectroscopy (1H-MRS). METHODS: Skeletal muscle imaging of the lower extremities was performed in 31 patients with genetically confirmed GNE myopathy, including T1-weighted and short tau inversion recovery (STIR) images, T1 and T2 mapping, and 1H-MRS. Measures evaluated included longitudinal relaxation time (T1), transverse relaxation time (T2), and 1H-MRS fat fraction (FF). Thigh muscle volume was correlated with relevant measures of strength, function, and patient-reported outcomes. RESULTS: The cohort was representative of a wide range of disease progression. Contractile thigh muscle volume ranged from 5.51% to 62.95% and correlated with thigh strength (r = 0.91), the 6-minute walk test (r = 0.82), the adult myopathy assessment tool (r = 0.83), the activities-specific balance confidence scale (r = 0.65), and the inclusion body myositis functional rating scale (r = 0.62). Four stages of muscle involvement were distinguished by qualitative (T1W and STIR images) and quantitative methods: stage I: unaffected muscle (T1 = 1,033 ± 74.2 ms, T2 = 40.0 ± 1.9 ms, FF = 7.4 ± 3.5%); stage II: STIR hyperintense muscle with minimal or no fat infiltration (T1 = 1,305 ± 147 ms, T2 = 50.2 ± 3.5 ms, FF = 27.6 ± 12.7%); stage III: fat infiltration and STIR hyperintensity (T1 = 1,209 ± 348 ms, T2 = 73.3 ± 12.6 ms, FF = 57.5 ± 10.6%); and stage IV: complete fat replacement (T1 = 318 ± 39.9 ms, T2 = 114 ± 21.2 ms, FF = 85.6 ± 4.2%). 1H-MRS showed a significant decrease in intramyocellular lipid and trimethylamines between stage I and II, suggesting altered muscle metabolism at early stages. CONCLUSION: MRI biomarkers can monitor muscle involvement and determine disease severity noninvasively in patients with GNE myopathy. CLINICALTRIALSGOV IDENTIFIER: NCT01417533.
OBJECTIVE: To characterize muscle involvement and evaluate disease severity in patients with GNE myopathy using skeletal muscle MRI and proton magnetic resonance spectroscopy (1H-MRS). METHODS: Skeletal muscle imaging of the lower extremities was performed in 31 patients with genetically confirmed GNE myopathy, including T1-weighted and short tau inversion recovery (STIR) images, T1 and T2 mapping, and 1H-MRS. Measures evaluated included longitudinal relaxation time (T1), transverse relaxation time (T2), and 1H-MRS fat fraction (FF). Thigh muscle volume was correlated with relevant measures of strength, function, and patient-reported outcomes. RESULTS: The cohort was representative of a wide range of disease progression. Contractile thigh muscle volume ranged from 5.51% to 62.95% and correlated with thigh strength (r = 0.91), the 6-minute walk test (r = 0.82), the adult myopathy assessment tool (r = 0.83), the activities-specific balance confidence scale (r = 0.65), and the inclusion body myositis functional rating scale (r = 0.62). Four stages of muscle involvement were distinguished by qualitative (T1W and STIR images) and quantitative methods: stage I: unaffected muscle (T1 = 1,033 ± 74.2 ms, T2 = 40.0 ± 1.9 ms, FF = 7.4 ± 3.5%); stage II: STIR hyperintense muscle with minimal or no fat infiltration (T1 = 1,305 ± 147 ms, T2 = 50.2 ± 3.5 ms, FF = 27.6 ± 12.7%); stage III: fat infiltration and STIR hyperintensity (T1 = 1,209 ± 348 ms, T2 = 73.3 ± 12.6 ms, FF = 57.5 ± 10.6%); and stage IV: complete fat replacement (T1 = 318 ± 39.9 ms, T2 = 114 ± 21.2 ms, FF = 85.6 ± 4.2%). 1H-MRS showed a significant decrease in intramyocellular lipid and trimethylamines between stage I and II, suggesting altered muscle metabolism at early stages. CONCLUSION: MRI biomarkers can monitor muscle involvement and determine disease severity noninvasively in patients with GNE myopathy. CLINICALTRIALSGOV IDENTIFIER: NCT01417533.
Authors: Garry E Gold; Eric Han; Jeff Stainsby; Graham Wright; Jean Brittain; Christopher Beaulieu Journal: AJR Am J Roentgenol Date: 2004-08 Impact factor: 3.959
Authors: Nicholas J Tustison; Brian B Avants; Philip A Cook; Yuanjie Zheng; Alexander Egan; Paul A Yushkevich; James C Gee Journal: IEEE Trans Med Imaging Date: 2010-04-08 Impact factor: 10.048
Authors: Gustav J Strijkers; Ericky C A Araujo; Noura Azzabou; David Bendahan; Andrew Blamire; Jedrek Burakiewicz; Pierre G Carlier; Bruce Damon; Xeni Deligianni; Martijn Froeling; Arend Heerschap; Kieren G Hollingsworth; Melissa T Hooijmans; Dimitrios C Karampinos; George Loudos; Guillaume Madelin; Benjamin Marty; Armin M Nagel; Aart J Nederveen; Jules L Nelissen; Francesco Santini; Olivier Scheidegger; Fritz Schick; Christopher Sinclair; Ralph Sinkus; Paulo L de Sousa; Volker Straub; Glenn Walter; Hermien E Kan Journal: J Neuromuscul Dis Date: 2019
Authors: Martin Krššák; Lucas Lindeboom; Vera Schrauwen-Hinderling; Lidia S Szczepaniak; Wim Derave; Jesper Lundbom; Douglas Befroy; Fritz Schick; Jürgen Machann; Roland Kreis; Chris Boesch Journal: NMR Biomed Date: 2020-02-05 Impact factor: 4.044
Authors: Jasper M Morrow; Christopher D J Sinclair; Arne Fischmann; Pedro M Machado; Mary M Reilly; Tarek A Yousry; John S Thornton; Michael G Hanna Journal: Lancet Neurol Date: 2015-11-06 Impact factor: 44.182
Authors: Peter Kellman; W Patricia Bandettini; Christine Mancini; Sophia Hammer-Hansen; Michael S Hansen; Andrew E Arai Journal: J Cardiovasc Magn Reson Date: 2015-05-10 Impact factor: 5.364